Diagnostic Revenues Drive up CombiMatrix Q2 Revenues 31 Percent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix today reported a 31 percent increase year over year in its second-quarter revenues on an uptick in its diagnostic testing service revenues.

For the three months ended June 30, the firm posted revenues of $1.2 million, compared to $916,000 a year ago. Total revenues were comprised completely of diagnostic testing revenues, which rose 51 percent from $796,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.